Lifecore Biomedical, Inc. (NASDAQ:LFCR – Get Free Report) has been assigned an average rating of “Reduce” from the five research firms that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and three have issued a hold rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $6.50.
Several research analysts have commented on the company. Weiss Ratings raised Lifecore Biomedical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 16th. Zacks Research cut Lifecore Biomedical from a “hold” rating to a “strong sell” rating in a research note on Friday, November 6th. Craig Hallum downgraded shares of Lifecore Biomedical from a “strong-buy” rating to a “hold” rating in a report on Monday, September 28th. William Blair lowered Lifecore Biomedical from an “outperform” rating to a “hold” rating in a research note on Monday, September 28th. Finally, Barrington Research lowered shares of Lifecore Biomedical from an “outperform” rating to a “hold” rating in a research report on Tuesday, September 29th.
Get Our Latest Analysis on LFCR
Institutional Investors Weigh In On Lifecore Biomedical
Lifecore Biomedical Stock Performance
Shares of NASDAQ:LFCR opened at $6.39 on Thursday. Lifecore Biomedical has a 52 week low of $3.63 and a 52 week high of $8.98. The company has a 50 day moving average price of $6.01 and a two-hundred day moving average price of $5.39. The company has a market capitalization of $242.24 million, a PE ratio of -3.44 and a beta of 0.99.
Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.78). The company had revenue of $25.32 million during the quarter, compared to analyst estimates of $25.57 million. On average, sell-side analysts forecast that Lifecore Biomedical will post -1.83 earnings per share for the current year.
Lifecore Biomedical Company Profile
Lifecore Biomedical, Inc. is a contract development and manufacturing organization (CDMO) focused on sterile injectable pharmaceutical products. The company works with customers on product development, formulation, analytical testing, regulatory support and commercial-scale manufacturing, including fill-finish services. Lifecore also develops and manufactures hyaluronic acid, a biopolymer used in medical products and other applications. Its capabilities support products in areas such as ophthalmology and orthopedics, as well as pharmaceutical and veterinary uses.
Featured Stories
- Five stocks we like better than Lifecore Biomedical
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
